摘要
钙结合蛋白S100B作为多种疾病的生物标志物备受关注,S100B蛋白主要表达于神经胶质细胞,通过细胞内和细胞外的信号转导通路起作用。S100B蛋白的生物学作用与浓度和生理状态密切相关,释放的S100B与晚期糖基化终产物受体相关并且诱导了多种细胞信号转导的起始点。据说S100B生物活性的调节是通过磷脂酰肌醇3激酶/ Akt,p53,丝裂原活化蛋白激酶,包括核因子-kappaB和环磷酸腺的转录因子来实现的。血液中S100B的水平能预测多种疾病的进展或预后,如脑血管疾病,神经退行性疾病,运动神经元疾病,创伤性脑损伤,精神分裂症,抑郁症,糖尿病,心肌梗塞,癌症和传染病等。鉴于S100B的活动与这些疾病的病理过程相关,S100B不应该被简单地视为一种生物标志物,它可以作为对这些疾病的治疗目标。进一步阐明S100B的作用以制定多种疾病创新的治疗策略。
关键词: RAGE;PI3K;MAPK;神经退行性疾病;中风;糖尿病;生物标志物。
Current Medicinal Chemistry
Title:Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Volume: 23 Issue: 15
Author(s): Zhao Zhong Chong, Benjarat Changyaleket, Haoliang Xu, Randy O. Dull, David E. Schwartz
Affiliation:
关键词: RAGE;PI3K;MAPK;神经退行性疾病;中风;糖尿病;生物标志物。
摘要: The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.
Export Options
About this article
Cite this article as:
Zhao Zhong Chong, Benjarat Changyaleket, Haoliang Xu, Randy O. Dull, David E. Schwartz , Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases, Current Medicinal Chemistry 2016; 23 (15) . https://dx.doi.org/10.2174/0929867323666160406121117
DOI https://dx.doi.org/10.2174/0929867323666160406121117 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Support of Neurorehabilitation
Current Drug Therapy Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Resveratrol Protects Endothelial Cells from Rapid Stretch Injury and Hypoxia In Vitro
Current Drug Therapy Mild Cognitive Impairment (MCI) - The Novel Trend of Targeting Alzheimers Disease in Its Early Stages - Methodological Considerations
Current Alzheimer Research Conference Report: 182nd AAAS Annual Meeting, Washington DC, February 11-15, 2016
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 11
Protein & Peptide Letters Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Transient Blood Brain Barrier Disruption Induced by Oleic Acid is Mediated by Nitric Oxide
Current Neurovascular Research Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Biological Responses to Hydrogen Molecule and its Preventive Effects on Inflammatory Diseases
Current Pharmaceutical Design Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets